CSLLY
CSLLY
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
CSLLY
Expected move
No implied move.
CSL Ltd
Price unavailable.
−2.78%
shares held · 5 largest managers
0.04%
CSLLY weight · VT
No changes.
No changes.
No trades yet today.
No trades yet today.
| Manager | Value | % base | |
|---|---|---|---|
| Rhumbline | $480,811 | 91.27% | −4.79% |
| Salomon & Ludwin | $40,857 | 7.76% | +24.33% |
| PNC Financial Services | $4,413 | 0.84% | +33.33% |
| TrueNorth | $582 | 0.11% | +45.00% |
| First Command Advisory Services | $120 | 0.02% | +50.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Rhumbline | $480,811 | 91.27% | −4.79% |
| Salomon & Ludwin | $40,857 | 7.76% | +24.33% |
| PNC Financial Services | $4,413 | 0.84% | +33.33% |
| TrueNorth | $582 | 0.11% | +45.00% |
| First Command Advisory Services | $120 | 0.02% | +50.00% |
No peers for CSLLY yet.
No peers for CSLLY yet.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Annual filing, not covered
Not parsed · ties from counterparty filings
13F holdings, not covered
Not loaded
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Annual filing, not covered
Not parsed · ties from counterparty filings
13F holdings, not covered
Not loaded
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.